CLINICAL TRIALS PROFILE FOR LOMOTIL

All Clinical Trials for LOMOTIL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00583323 ↗	Diphenoxylate / Atropine to Decrease FDG Activity During F-18 FDG PET	Completed	Mayo Clinic	Phase 3	2003-02-01	2-[18F]-fluoro-2-deoxyD-glucose positron emission tomography (FDG PET) has proven to be a valuable clinical tool for the staging and surveillance of lymphoma.1-6 Occasionally, lymph nodes in the mesentery and retroperitoneum can be difficult to distinguish from normal bowel activity on PET scans despite three-plane and cine maximal image projection (MIP) imaging. This uncertainty limits the clinical usefulness of PET in some cases of lymphoma.7-8 In addition, bowel activity can also hinder interpretation of PET scans in other types of solid tumors including melanoma and colorectal cancer.6,9,10 Our goal is to determine how well diphenoxylate/atropine 5mg/0.05mg (Lomotil) decreases bowel activity and how this decrease impacts clinical decision-making, specifically for lymphoma staging and surveillance. This is a prospective, randomized, double-blinded study involving 60 patients undergoing PET scans for newly diagnosed or recurrent, untreated lymphoma.
NCT00591357 ↗	Efficacy of Loperamide for C. Difficile Colitis and Other Diarrheal Diseases Associated With Antibiotic Therapy	Suspended	Michael E. DeBakey VA Medical Center	Phase 4	2007-10-01	To determine whether symptomatic treatment of the diarrhea in CDAD reduces morbidity and mortality of this serious nosocomial infection in patients who have antibiotic-associated diarrhea. Both C. diff positive and negative patients will be included.
NCT00591357 ↗	Efficacy of Loperamide for C. Difficile Colitis and Other Diarrheal Diseases Associated With Antibiotic Therapy	Suspended	VA Medical Center, Houston	Phase 4	2007-10-01	To determine whether symptomatic treatment of the diarrhea in CDAD reduces morbidity and mortality of this serious nosocomial infection in patients who have antibiotic-associated diarrhea. Both C. diff positive and negative patients will be included.
NCT02018653 ↗	CASAD for Severe Diarrhea in the Emergency Department	Terminated	Salient Pharmaceuticals Incorporated	N/A	2013-12-01	The goal of this clinical research study is to learn if calcium alumina-silicate (CASAD) can help to stop your diarrhea. Researchers also want to know if this drug can help decrease the duration of your diarrhea. In this study, CASAD will be compared to a placebo. A placebo is not a drug. It looks like the study drug but it is not designed to treat any disease or illness. It is designed in this study to be compared with the study drug to learn if the study drug has any real effect.
NCT02018653 ↗	CASAD for Severe Diarrhea in the Emergency Department	Terminated	M.D. Anderson Cancer Center	N/A	2013-12-01	The goal of this clinical research study is to learn if calcium alumina-silicate (CASAD) can help to stop your diarrhea. Researchers also want to know if this drug can help decrease the duration of your diarrhea. In this study, CASAD will be compared to a placebo. A placebo is not a drug. It looks like the study drug but it is not designed to treat any disease or illness. It is designed in this study to be compared with the study drug to learn if the study drug has any real effect.
NCT03094052 ↗	Incidence and Severity of Diarrhea in Patients With Stage II-IIIC HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib	Recruiting	Napo Pharmaceuticals, Inc.	Phase 2	2018-10-09	This phase II trial studies the incidence and severity of diarrhea in patients with stage II-IIIC HER2 Positive breast cancer treated with trastuzumab and neratinib. Trastuzumab is a form of targeted therapy because it attaches itself to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the body's immune system. Neratinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving trastuzumab and neratinib may work better in treating patients with stage II-IIIC HER2 positive breast cancer.

Clinical Trial Conditions for LOMOTIL

Condition Name

Condition Name for LOMOTIL
Intervention	Trials
Stage IIA Breast Cancer AJCC v6 and v7	1
Stage IIB Breast Cancer AJCC v6 and v7	1
Antibiotic-Associated Diarrhea	1
Stage III Breast Cancer AJCC v7	1

Condition MeSH

Condition MeSH for LOMOTIL
Intervention	Trials
Diarrhea	3
Breast Neoplasms	1
Emergencies	1
Colitis	1

Clinical Trial Locations for LOMOTIL

Trials by Country

Trials by Country for LOMOTIL
Location	Trials
United States	4

Trials by US State

Trials by US State for LOMOTIL
Location	Trials
California	2
Texas	2

Clinical Trial Progress for LOMOTIL

Clinical Trial Phase

Clinical Trial Phase for LOMOTIL
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status for LOMOTIL
Clinical Trial Phase	Trials
Suspended	1
Active, not recruiting	1
Terminated	1

Clinical Trial Sponsors for LOMOTIL

Sponsor Name

Sponsor Name for LOMOTIL
Sponsor	Trials
M.D. Anderson Cancer Center	1
Napo Pharmaceuticals, Inc.	1
Puma Biotechnology, Inc.	1

Sponsor Type

Sponsor Type for LOMOTIL
Sponsor	Trials
Industry	5
Other	3
U.S. Fed	2